The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.
RetinalGeniX™ Technologies, Inc. previewed the completion of an Institutional Review Board (IRB) for research on its DNA/GPS program. Through this research, the company aims to offer recommendations for enhancing the management of ocular injections. These injections have become a significant healthcare burden due to their associated complications in treating macular degeneration-related vision loss.
Larry Perich, DO, Director of the DNA/GPS program at RetinalGeniX shared the intentions for this study and its expected impact on the ophthalmology field. In the press release, he said, "We are near completion of an IRB for research on its DNA/GPS program. We intend to conduct the study on 100 patients in an effort to establish standards for determining effective and ineffective eye injections for treating macular degeneration, the leading cause of retinal blindness. The study will follow global standards for ophthalmology research to ensure that the resulting biomarkers can be universally applied. We expect this will help in better management of the condition."
Perich plans to lead the collaborative study among leading universities to identify hematology biomarkers. The goal of the study is to personalize medical evaluations for patients receiving treatment for macular degeneration.
The National Center for Biotechnology Information NCBI / NIH states, "Age-related macular degeneration (AMD) affects 1 in 8 people 60 years of age or older and is the most common cause of irreversible blindness in older persons in developed countries. According to thorough estimates, 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million."